Cancers showing overexpression of MYEOV transcripts include multiple myeloma (Moreaux et al., 2010), breast cancer (Janssen et al., 2002a), esophageal squamous cell carcinomas (Janssen et al., 2002b), gastric cancer (Leyden et al., 2006), colon cancer (Moss et al., 2006), neuroblastoma (Takita et al., 2011) and, more recently, pancreatic ductal adenocarcinoma (PDAC) (Fang et al., 2019; Liang et al., 2020) and non-small cell lung cancer (NSCLC) (Fang et al., 2019). Here, MYEOV is linked to plasma cell myeloma.